Mediators of Inflammation

Mediators of Inflammation / 2016 / Article

Corrigendum | Open Access

Volume 2016 |Article ID 7267956 | 1 page | https://doi.org/10.1155/2016/7267956

Corrigendum to “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease”

Received05 Oct 2016
Accepted20 Oct 2016
Published14 Nov 2016

In the article titled “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease” [1], reference [] was incorrectly added as follows:“Y. Chen, S.-C. Xu, and R.-D. Duan, ‘Mevalonate inhibits acid sphingomyelinase activity, increases sphingomyelin levels and inhibits cell proliferation of HepG2 and Caco-2 cells,’ Lipids in Health and Disease, vol. 14, no. 1, article 130, 2015.”It should be replaced with the following reference:“Chen Y, et al. Enhanced colonic tumorigenesis in alkaline sphingomyelinase (NPP7) knockout mice. Mol Cancer Ther, 14:1, 259-67, 2015.”

References

  1. P.-F. Bryan, C. Karla, M.-T. Edgar Alejandro, E.-P. Sara Elva, F. Gemma, and C. Luz, “Sphingolipids as mediators in the crosstalk between microbiota and intestinal cells: implications for inflammatory bowel disease,” Mediators of Inflammation, vol. 2016, Article ID 9890141, 11 pages, 2016. View at: Publisher Site | Google Scholar

Copyright © 2016 Bryan Phillips-Farfán et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

388 Views | 211 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.